Miniatura

Fitxers

693992.pdf (1.45 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-07-02

Llicència de publicació

cc-by (c) Cobo-Calvo, Alvaro et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/164272

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s12974-019-1525-1

Resum

Background: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. Methods: This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Results: Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. Conclusion: In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD.

Matèries

Immunoglobulines, Esclerosi múltiple, Terapèutica

Matèries (anglès)

Immunoglobulins, Multiple sclerosis, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

COBO-CALVO, Alvaro, SEPÚLVEDA, María, ROLLOT, Fabien, ARMANGUÉ, Thaís, RUIZ, Anne, MAILLART, Elisabeth, PAPEIX, Caroline, AUDOIN, Bertrand, ZEPHIR, Helene, BIOTTI, Damien, CIRON, Jonathan, DURAND-DUBIEF, Francoise, COLLONGUES, Nicolas, AYRIGNAC, Xavier, LABAUGE, Pierre, THOUVENOT, Eric, BOURRE, Bertrand, MONTCUQUET, Alexis, COHEN, Mikael, DESCHAMPS, Romain, SOLA VALLS, Nuria, LLUFRIU DURAN, Sara, DE, Seze, BLANCO MORGADO, Yolanda, VUKUSIC, Sandra, SAIZ HINAREJOS, Albert, MARIGNIER, Romain. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. _Journal of Neuroinflammation_. 2019. Vol. 16, núm. 134. [consulta: 25 de febrer de 2026]. ISSN: 1742-2094. [Disponible a: https://hdl.handle.net/2445/164272]

Exportar metadades

JSON - METS

Compartir registre